3 recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Recruiting 3 |
Follow ALKS 2680 Dose 1: new trials by email Literature Review of ALKS 2680 Dose 1 trials Research Report on ALKS 2680 Dose 1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304) ALKS 2680 Dose 1, ALKS 2680 Dose 2, Placebo - Narcolepsy Type 1 | Phase 3 | Recruiting | Alkermes, Inc. | 150 | 2026-08-13 | 2026-10-07 |
| A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 ALKS 2680 Dose 1, ALKS 2680 Dose 2, ALKS 2680 Dose 3 - Narcolepsy Type 2 | Phase 3 | Recruiting | Alkermes, Inc. | 176 | 2026-04-22 | 2026-10-07 |
| A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 ALKS 2680 Dose 1, ALKS 2680 Dose 2, Placebo - Narcolepsy Type 1 | Phase 3 | Recruiting | Alkermes, Inc. | 150 | 2026-04-06 | 2026-10-07 |
Disorders of Excessive Somnolence (3) · Sleep Wake Disorders (3) · Cataplexy (1) · Fatigue (1) · Narcolepsy (1) · Sleepiness (1)
Alkermes, Inc. (3)
Belgium (3) · Canada (3) · Japan (3) · United States (3) · Australia (2) · France (2) · Italy (2) · Netherlands (2) · Spain (2) · Taiwan (2) · Poland (1)